RegeneRx Biopharmaceuticals, Inc.
RGRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$898
Close$
$-0.01
1833.3% downside
Current Fair Value
1833.3% downsideOvervalued by 1833.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $898.00 |
|---|---|
| Enterprise Value | $898.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1 |
| Beta | 4.73 |
| Outstanding Shares | 143,500,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | 0.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.02 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About RegeneRx Biopharmaceuticals, Inc.
2 employees
CEO: Mr. J. J. Finkelstein RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservat...